The North Carolina Biotechnology Center this week said that Arthur Pappas has been elected chairman of the NCBC’s board of directors.
Pappas is founder and managing partner of Pappas Ventures, a Research Triangle Park-based venture capital firm. Before founding the firm in 1994, Pappas held senior leadership positions at several pharmaceutical companies, including Glaxo Holdings, Abbott, and Dow.
He is also the founding CEO and chairman of Durham-based CoLucid Pharmaceuticals, and currently serves as a director of Genstruct, LEAD Therapeutics, and TyRx Pharma.
Pappas earned an MBA in finance from Xavier University. He is also a decorated Vietnam veteran, having served as an officer in the US Army 101st Airborne Division and the Special Forces.
The NCBC also said it elected Patricia Morton as vice chair; re-elected John Atkins as treasurer; and re-elected Jack Cecil as secretary.
The Pennsylvania Biotechnology Center of Bucks County has named Ethan Byler as director of biotechnology development.
Byler joins the organization from New Economy Strategies, a consulting company focused on technology-based economic development in Washington, DC. Byler has also served as an analyst for federal funding programs with Innovation Philadelphia.
He holds a masters degree in government administration from the Fels Institute of Government at the University of Pennsylvania, and a BA from the University of Charleston.
Hydra Biosciences said last week that Christine Bellon has been appointed vice president of IP and legal affairs.
Bellon joins Hydra from Infinity Pharmaceuticals, where she served as assistant general counsel, intellectual property. Prior to this, she served as patent counsel at Wyeth Pharmaceuticals. She has also served as an attorney with Fish and Richardson.
She holds a BS in chemistry from Yale University, a PhD in organic chemistry from the Massachusetts Institute of Technology, and a JD degree from Columbia Law School.
Diane Dobrea and Joel Cloud have joined Dinsmore & Shohl’s intellectual property practice group in Columbus, Ohio.
The attorneys join Dinsmore & Shohl from Hahn, Loeser & Parks.
In a statement, the law firm said that the new employees would significantly add to its biotechnology patent prosecution and transactional work.